TITLE

Chylous ascites following treatment for chronic lymphocytic leukemia

AUTHOR(S)
Jasti, Kishan K; Myneni, Anjana; Lichtenstein, Steven
PUB. DATE
September 2003
SOURCE
American Journal of Gastroenterology;Sep2003 Supplement, Vol. 98, pS155
SOURCE TYPE
Academic Journal
DOC. TYPE
Abstract
ABSTRACT
An abstract of the article "Chylous Ascites Following Treatment for Chronic Lymphocytic Leukemia," by Kishan K. Jasti, Anjana Myneni, and Steven Lichtenstein is presented.
ACCESSION #
66955049

 

Related Articles

  • Cladribine combined with cyclophosphamide is highly effective in the treatment of chronic lymphocytic leukemia. Robak, Tadeusz; Błoński, Jerzy Z; Kasznicki, Marek; Góra-Tybor, Joanna; Dwilewicz-Trojaczek, Jadwiga; Stella-Hołowiecka, Beata; Wołowiec, Dariusz // Hematology Journal;2002, Vol. 3 Issue 5, p244 

    The aim of the study was to evaluate the activity and toxicity of cladribine (2-CdA) in combination with cyclophosphamide (CY), the CC schedule, in patients with previously untreated B-cell chronic lymphocytic leukemia (B-CLL). From November 1998 to May 2002 82 patients with advanced or...

  • New combination therapy improved OS in patients with CLL. Cona, Christen; Harris, Jason; Southall, Jennifer // Hem/Onc Today;10/25/2010, Vol. 11 Issue 20, p27 

    The article discusses research being done on the effectiveness of combining rituximab, fludarabine and cyclophosphamide for prolonging the lives of chronic lymphocytic leukemia patients, which references a study by Peter Hillmen and colleagues in a 2010 issue of the journal "Lancet."

  • Sporadic and reversible chromothripsis in chronic lymphocytic leukemia revealed by longitudinal genomic analysis. Bassaganyas, L; Beà, S; Escaramís, G; Tornador, C; Salaverria, I; Zapata, L; Drechsel, O; Ferreira, P G; Rodriguez-Santiago, B; Tubio, J M C; Navarro, A; Martín-García, D; López, C; Martínez-Trillos, A; López-Guillermo, A; Gut, M; Ossowski, S; López-Otín, C; Campo, E; Estivill, X // Leukemia (08876924);Mar2015, Vol. 29 Issue 3, p758 

    A correction to the article "Sporadic and reversible chromothripsis in chronic lymphocytic leukemia revealed by longitudinal genomic analysis," that was published in previous issue is presented.

  • Long-term outcomes in patients with CLL better with fludarabine vs. chlorambucil.  // Hem/Onc Today;1/25/2010, Vol. 11 Issue 2, p44 

    The article focuses on a study which found that patients with chronic lymphocytic leukemia intially treated with fludarabine demonstrated better overall survival (OS) and progression free survival (PFS) than those treated with chlorambucil.

  • Cladribine combined with cyclophosphamide and mitoxantrone as front-line therapy in chronic lymphocytic leukemia. Robak, T; Błoński, J Z; Kasznicki, M; Góra-Tybor, J; Dwilewicz-Trojaczek, J; Boguradzki, P; Konopka, L; Ceglarek, B; Sułek, J; Kuliczkowski, K; Wołowiec, D; Stella-Hołowiecka, B; Skotnicki, A B; Nowak, W; Moskwa-Sroka, B; Dmoszyńska, A; Calbecka, M // Leukemia (08876924);Oct2001, Vol. 15 Issue 10, p1510 

    The objective of the study was to determine the effectiveness and the toxicity of a combined chemotherapy consisting of cladribine (2-CdA), mitoxantrone and cyclophosphamide (CMC regimen) in the treatment of previously untreated B cell chronic lymphocytic leukemia (B-CLL). From August 1998 to...

  • Chemoimmunotherapy extended OS, PFS in patients with CLL.  // Hem/Onc Today;3/25/2011, Vol. 12 Issue 6, p33 

    The article reports that fludarabine with rituximab extended progression-free survival (PFS) and overall survival (OS) in chronic lymphocytic leukemia patients after long-term follow-up, which is based on a study conducted by J. A. Woyach and colleagues.

  • Rituximab: A Review of its Use in Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukaemia. Plosker, Greg L.; Figgitt, David P. // Drugs;2003, Vol. 63 Issue 8, p803 

    Rituximab is an anti-CD20 monoclonal antibody that has demonstrated efficacy in patients with various lymphoid malignancies, including indolent and aggressive forms of B-cell non-Hodgkin's lymphoma (NHL) and B-cell chronic lymphocytic leukaemia (CLL). While the optimal use of the drug in many...

  • Oral Fludarabine: A Viewpoint by Bruce D. Cheson. Cheson, Bruce D. // Drugs;2003, Vol. 63 Issue 21, p2324 

    Comments on the use of purine analogue fludarabine in treatment of the indolent lymphoid malignancy chronic lymphocytic leukemia (CLL). Superiority of fludarabine to other drugs demonstrated by clinical trials; Administration of fludarabine; Use of monoclonal antibodies alemtuzumab and...

  • Oral Fludarabine: A Viewpoint by David Oscier. Oscier, David // Drugs;2003, Vol. 63 Issue 21, p2324 

    Focuses on the use of purine nucleoside analogue fludarabine in the treatment of chronic lymphocytic leukemia (CLL). Efficacy and adverse effects of oral fludarabine; Advantages of oral preparation of the drug; Gastrointestinal adverse effects experienced by some patients with CLL.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics